Next Article in Journal
How Far Are We from Prescribing Fasting as Anticancer Medicine?
Previous Article in Journal
Versatile Types of Polysaccharide-Based Drug Delivery Systems: From Strategic Design to Cancer Therapy
 
 
Review
Peer-Review Record

Isocyanide Multicomponent Reactions on Solid Phase: State of the Art and Future Application

Int. J. Mol. Sci. 2020, 21(23), 9160; https://doi.org/10.3390/ijms21239160
by Naděžda Cankařová 1,* and Viktor Krchňák 1,2
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2020, 21(23), 9160; https://doi.org/10.3390/ijms21239160
Submission received: 17 November 2020 / Revised: 27 November 2020 / Accepted: 28 November 2020 / Published: 1 December 2020
(This article belongs to the Section Macromolecules)

Round 1

Reviewer 1 Report

This is an almost perfect review!

Possible improvement in several reaction schemes: The formula of the following aldehydes should be redrawn with a longer single bond between the substituent (R1, R2 etc.)  and the formyl carbon atom: 11, 18, 93, 113, 125, 135, 141, 147, 154, 163, 168, 185, 209, 215, 227, 248, 254, 259, 277, 287, 296, 317, 323, 388, 401, 405, 409, 419, 424, 430, 435, 456, and 459.

See attached PDF document produced with ChemDraw.

Comments for author File: Comments.pdf

Author Response

Reviewer 1

Possible improvement in several reaction schemes: The formula of the following aldehydes should be redrawn with a longer single bond between the substituent (R1, R2 etc.)  and the formyl carbon atom: 11, 18, 93, 113, 125, 135, 141, 147, 154, 163, 168, 185, 209, 215, 227, 248, 254, 259, 277, 287, 296, 317, 323, 388, 401, 405, 409, 419, 424, 430, 435, 456, and 459.

Response:

The formula of the following aldehydes was redrawn with a longer single bond between the R substituent and the formyl carbon:

  • Structure 11 in Scheme 1, line 81
  • Structure 18 in Scheme 2, line 88
  • Structure 93 in Scheme 19, line 356
  • Structure 113 in Scheme 24, line 404
  • Structure 125 in Scheme 26, line 433
  • Structure 135 in Scheme 28, line 448
  • Structure 141 in Scheme 29, line 466
  • Structure 147 in Scheme 30, line 479
  • Structure 154 in Scheme 31, line 494
  • Structure 163 in Scheme 32, line 511
  • Structure 168 in Scheme 33, line 520
  • Structure 185 in Scheme 36, line 556
  • Structure 209 in Scheme 37, line 581
  • Structure 215 in Scheme 38, line 593
  • Structure 227 in Scheme 40, line 614
  • Structure 248 in Scheme 43, line 653
  • Structure 254 in Scheme 44, line 659
  • Structure 259 in Scheme 45, line 668
  • Structure 277 in Scheme 48, line 713
  • Structure 287 in Scheme 49, line 727
  • Structure 296 in Scheme 50, line 741
  • Structure 317 in Scheme 52, line 768
  • Structure 323 in Scheme 53, line 780
  • Structure 18 in Scheme 54, line 796
  • Structure 388 in Scheme 65, line 918
  • Structure 401 in Scheme 67, line 937
  • Structure 405 in Scheme 68, line 942
  • Structure 409 in Scheme 69, line 953
  • Structure 419 in Scheme 71, line 967
  • Structure 424 in Scheme 72, line 987
  • Structure 430 in Scheme 73, line 998
  • Structure 435 in Scheme 74, line 1006
  • Structure 456 in Scheme 77, line 1057
  • Structure 459 in Scheme 78, line 1066

Reviewer 2 Report

The authors have well described about the solid-phase syntheses of heterocycles involving isocyanide-based multicomponent reactions in this review. Though there are lot of reviews reported on MCRs, the present review has it own contribution towards the solid-phase applications of IMCRs. I would like to request the honorable editor to accept the review in its present form.

Author Response

Reviewer 2

No changes were requested.

Back to TopTop